Biblio
Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant: Donor-derived malignancy and genetic risks in allo-HSCT. Transplant Cell Ther. 2023.
. Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Adv. 2021;5(9):2403-2411.
Shorter Interdonation Interval Contributes to Lower Cell Counts in Subsequent Stem Cell Donations. Transplant Cell Ther. 2021.